JP2023526024A5 - - Google Patents
Info
- Publication number
- JP2023526024A5 JP2023526024A5 JP2022568632A JP2022568632A JP2023526024A5 JP 2023526024 A5 JP2023526024 A5 JP 2023526024A5 JP 2022568632 A JP2022568632 A JP 2022568632A JP 2022568632 A JP2022568632 A JP 2022568632A JP 2023526024 A5 JP2023526024 A5 JP 2023526024A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- polypeptide
- kit
- kit according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022860P | 2020-05-11 | 2020-05-11 | |
| US63/022,860 | 2020-05-11 | ||
| PCT/US2021/031616 WO2021231319A1 (en) | 2020-05-11 | 2021-05-10 | Il-2 fusion polypeptide compositions and methods of making and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526024A JP2023526024A (ja) | 2023-06-20 |
| JP2023526024A5 true JP2023526024A5 (enExample) | 2024-05-17 |
Family
ID=78524880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568632A Pending JP2023526024A (ja) | 2020-05-11 | 2021-05-10 | Ｉｌ－２融合ポリペプチド組成物ならびにその作製及び使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210395325A1 (enExample) |
| EP (1) | EP4149514A4 (enExample) |
| JP (1) | JP2023526024A (enExample) |
| KR (1) | KR20230008759A (enExample) |
| CN (1) | CN115867307A (enExample) |
| AU (1) | AU2021269585A1 (enExample) |
| BR (1) | BR112022022869A2 (enExample) |
| CA (1) | CA3172874A1 (enExample) |
| IL (1) | IL298064A (enExample) |
| MX (1) | MX2022014163A (enExample) |
| TW (1) | TW202207971A (enExample) |
| WO (1) | WO2021231319A1 (enExample) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9156897B2 (en) * | 2012-06-08 | 2015-10-13 | Alkermes, Inc. | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide |
| AU2015236340B2 (en) * | 2014-03-24 | 2020-02-06 | Bioverativ Therapeutics Inc. | Lyophilized factor IX formulations |
| AU2015364396B2 (en) * | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
| UY37726A (es) * | 2017-05-05 | 2018-11-30 | Amgen Inc | Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados |
| WO2019019998A1 (zh) * | 2017-07-25 | 2019-01-31 | 江苏恒瑞医药股份有限公司 | 一种il-15蛋白复合物药物组合物及其用途 |
| BR112022007158A2 (pt) * | 2019-10-18 | 2022-07-05 | Alkermes Pharma Ireland Ltd | Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico |
-
2021
- 2021-05-10 US US17/315,974 patent/US20210395325A1/en not_active Abandoned
- 2021-05-10 BR BR112022022869A patent/BR112022022869A2/pt unknown
- 2021-05-10 IL IL298064A patent/IL298064A/en unknown
- 2021-05-10 CN CN202180040284.5A patent/CN115867307A/zh active Pending
- 2021-05-10 WO PCT/US2021/031616 patent/WO2021231319A1/en not_active Ceased
- 2021-05-10 JP JP2022568632A patent/JP2023526024A/ja active Pending
- 2021-05-10 CA CA3172874A patent/CA3172874A1/en active Pending
- 2021-05-10 EP EP21804274.5A patent/EP4149514A4/en active Pending
- 2021-05-10 AU AU2021269585A patent/AU2021269585A1/en not_active Abandoned
- 2021-05-10 KR KR1020227041366A patent/KR20230008759A/ko active Pending
- 2021-05-10 MX MX2022014163A patent/MX2022014163A/es unknown
- 2021-05-11 TW TW110116904A patent/TW202207971A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024099628A5 (enExample) | ||
| ES2409032T3 (es) | Formulaciones liofilizadas de vwf recombinante | |
| CN101272764B (zh) | hFSH水制剂 | |
| JP5753692B2 (ja) | タンパク質製剤 | |
| JP2005526084A5 (enExample) | ||
| ES2349472T3 (es) | Formulación estable de interferón pegilado. | |
| FI3328416T3 (fi) | C-tyypin natriureettisten peptidivarianttien käyttö luuston dysplasian hoidossa | |
| JP2019509311A5 (enExample) | ||
| JP2013163674A5 (enExample) | ||
| EP3156071A1 (en) | Stable aqueous adalimumab preparation | |
| JPH08245418A (ja) | 安定なトランスグルタミナーゼ製剤およびそれらを製造する方法 | |
| JP2023523218A5 (enExample) | ||
| JP2021529763A5 (enExample) | ||
| EP4595950A2 (en) | Annexin a1 n-terminal peptide formulations and methods | |
| EP2119451A1 (en) | Lyophilized preparation comprising influenza vaccine, and method for preparation thereof | |
| MX2023004426A (es) | Composiciones adecuadas para su uso en neonatos. | |
| ES2365832T3 (es) | Composiciones que comprenden conjugados de peg-interferón alfa y rafinosa como crioprotector. | |
| US12564619B2 (en) | Stable formulations of recombinant proteins | |
| JP2023526024A5 (enExample) | ||
| JP2021504349A5 (enExample) | ||
| JPS5940143B2 (ja) | ペプチド組成物の製法 | |
| JPH0818999B2 (ja) | インシュリン様成長因子ｉの乾燥製剤 | |
| US20230167162A1 (en) | Homing peptide-guided decorin conjugates for use in treating epidermolysis bullosa | |
| JP2024522855A5 (enExample) | ||
| JP2023525565A5 (enExample) |